S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.01 (+0.38%)
AAPL   115.40 (+1.15%)
MSFT   209.19 (+0.93%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,146.00 (+0.04%)
TSLA   428.70 (+2.30%)
NVDA   540.10 (+2.09%)
BABA   293.70 (+6.06%)
CGC   14.35 (-1.03%)
MU   46.87 (-7.57%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.41 (+0.39%)
F   6.62 (+0.30%)
ACB   4.64 (-0.85%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   123.90 (-1.20%)
BA   164.79 (+0.73%)
BAC   23.90 (+0.55%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.01 (+0.38%)
AAPL   115.40 (+1.15%)
MSFT   209.19 (+0.93%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,146.00 (+0.04%)
TSLA   428.70 (+2.30%)
NVDA   540.10 (+2.09%)
BABA   293.70 (+6.06%)
CGC   14.35 (-1.03%)
MU   46.87 (-7.57%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.41 (+0.39%)
F   6.62 (+0.30%)
ACB   4.64 (-0.85%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   123.90 (-1.20%)
BA   164.79 (+0.73%)
BAC   23.90 (+0.55%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.01 (+0.38%)
AAPL   115.40 (+1.15%)
MSFT   209.19 (+0.93%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,146.00 (+0.04%)
TSLA   428.70 (+2.30%)
NVDA   540.10 (+2.09%)
BABA   293.70 (+6.06%)
CGC   14.35 (-1.03%)
MU   46.87 (-7.57%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.41 (+0.39%)
F   6.62 (+0.30%)
ACB   4.64 (-0.85%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   123.90 (-1.20%)
BA   164.79 (+0.73%)
BAC   23.90 (+0.55%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.01 (+0.38%)
AAPL   115.40 (+1.15%)
MSFT   209.19 (+0.93%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,146.00 (+0.04%)
TSLA   428.70 (+2.30%)
NVDA   540.10 (+2.09%)
BABA   293.70 (+6.06%)
CGC   14.35 (-1.03%)
MU   46.87 (-7.57%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.41 (+0.39%)
F   6.62 (+0.30%)
ACB   4.64 (-0.85%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   123.90 (-1.20%)
BA   164.79 (+0.73%)
BAC   23.90 (+0.55%)
Log in
NASDAQ:MYL

Mylan Stock Forecast, Price & News

$14.83
+0.26 (+1.78 %)
(As of 09/30/2020 03:59 PM ET)
Add
Compare
Today's Range
$14.62
Now: $14.83▼
$14.98
50-Day Range
$14.21
MA: $15.73▼
$16.64
52-Week Range
$12.75
Now: $14.83▼
$23.11
Volume154,526 shs
Average Volume6.42 million shs
Market Capitalization$7.67 billion
P/E Ratio27.98
Dividend YieldN/A
Beta1.5
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More
Mylan logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.63 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MYL
Previous Symbol
CUSIP62853010
CIK1623613
Webwww.mylan.com
Phone724-514-1800

Debt

Debt-to-Equity Ratio0.84
Current Ratio0.93
Quick Ratio0.53

Price-To-Earnings

Trailing P/E Ratio27.98
Forward P/E Ratio3.34
P/E Growth2.11

Sales & Book Value

Annual Sales$11.50 billion
Price / Sales0.67
Cash Flow$7.85 per share
Price / Cash Flow1.89
Book Value$23.02 per share
Price / Book0.64

Profitability

EPS (Most Recent Fiscal Year)$4.42
Net Income$16.80 million
Net Margins2.35%
Return on Equity20.43%
Return on Assets7.72%

Miscellaneous

Employees35,000
Outstanding Shares516,947,000
Market Cap$7.67 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$14.83
+0.26 (+1.78 %)
(As of 09/30/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mylan (NASDAQ:MYL) Frequently Asked Questions

How has Mylan's stock price been impacted by Coronavirus (COVID-19)?

Mylan's stock was trading at $14.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MYL shares have increased by 2.5% and is now trading at $14.83.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Mylan?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mylan.

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Mylan.

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) released its quarterly earnings data on Thursday, August, 6th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.95 by $0.16. The business had revenue of $2.73 billion for the quarter, compared to analysts' expectations of $2.74 billion. Mylan had a net margin of 2.35% and a return on equity of 20.43%. The firm's revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.03 earnings per share.
View Mylan's earnings history.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12 billion, compared to the consensus revenue estimate of $11.62 billion.

What price target have analysts set for MYL?

9 analysts have issued 12-month price objectives for Mylan's shares. Their forecasts range from $17.00 to $27.00. On average, they expect Mylan's share price to reach $20.67 in the next year. This suggests a possible upside of 39.4% from the stock's current price.
View analysts' price targets for Mylan.

Are investors shorting Mylan?

Mylan saw a increase in short interest in August. As of August 31st, there was short interest totaling 44,100,000 shares, an increase of 20.3% from the August 15th total of 36,650,000 shares. Based on an average daily volume of 5,420,000 shares, the days-to-cover ratio is currently 8.1 days. Approximately 8.6% of the company's shares are sold short.
View Mylan's Short Interest.

Who are some of Mylan's key competitors?

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all competitors.

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Starbucks (SBUX) and General Electric (GE).

Who are Mylan's key executives?

Mylan's management team includes the following people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 50)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
  • Mr. Daniel M. Gallagher Jr., Advisor (Age 46)

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $14.83.

How big of a company is Mylan?

Mylan has a market capitalization of $7.67 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is www.mylan.com.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.